<?xml version="1.0" encoding="UTF-8"?>
<table-wrap position="float" id="tbl4">
 <label>Table 4</label>
 <caption>
  <p>Ongoing trials with chloroquine and hydroxychloroquine as of March 21, 2020.</p>
 </caption>
 <alt-text id="alttext0025">Table 4</alt-text>
 <table frame="hsides" rules="groups">
  <thead>
   <tr>
    <th>Study title</th>
    <th>Types of intervention</th>
    <th>Intervention vs. comparator</th>
    <th>n</th>
    <th>Country</th>
    <th>ClinicalTrial.Org identifier</th>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td align="left">Various Combination of Protease Inhibitors, Oseltamivir, Favipiravir, and Chloroquine for Treatment of COVID19: A Randomized Control Trial (THDMS-COVID19)</td>
    <td align="left">Treatment</td>
    <td align="left">Antiviral drugs plus Chloroquine PBO</td>
    <td align="left">80</td>
    <td align="left">Thailand</td>
    <td align="left">NCT04303299</td>
   </tr>
   <tr>
    <td align="left">Chloroquine Prevention of Coronavirus Disease (COVID-19) in the Healthcare Setting (COPCOV)</td>
    <td align="left">Prophylaxis</td>
    <td align="left">Chloroquine PBO</td>
    <td align="left">10,000</td>
    <td align="left">UK</td>
    <td align="left">NCT04303507</td>
   </tr>
   <tr>
    <td align="left">Treatment of Mild Cases and Chemoprophylaxis of Contacts as Prevention of the COVID-19 Epidemic (HCQ4COV19)</td>
    <td align="left">Treatment and prophylaxis in two separate groups</td>
    <td align="left">Darunavir/Cobicistat plus Chloroquine PBO</td>
    <td align="left">3040</td>
    <td align="left">Germany</td>
    <td align="left">NCT04304053</td>
   </tr>
   <tr>
    <td align="left">The Clinical Study of Carrimycin on Treatment Patients With COVID-19</td>
    <td align="left">Treatment</td>
    <td align="left">Carrimycin Lopinavir/ritonavir Arbidol Chloroquine PBO</td>
    <td align="left">520</td>
    <td align="left">China</td>
    <td align="left">NCT04286503</td>
   </tr>
   <tr>
    <td align="left">Comparison of Lopinavir/Ritonavir or Hydroxychloroquine in Patients with Mild Coronavirus Disease (COVID-19)</td>
    <td align="left">Treatment</td>
    <td align="left">Lopinavir/ritonavir HCQ</td>
    <td align="left">150</td>
    <td align="left">Korea</td>
    <td align="left">NCT04307693</td>
   </tr>
   <tr>
    <td align="left">Efficacy and Safety of Hydroxychloroquine for Treatment of Pneumonia Caused by 2019-nCoV (HC-nCoV)</td>
    <td align="left">Treatment</td>
    <td align="left">HCQ PBO</td>
    <td align="left">30</td>
    <td align="left">China</td>
    <td align="left">NCT04261517</td>
   </tr>
   <tr>
    <td align="left">Post-exposure Prophylaxis for SARS-Coronavirus-2</td>
    <td align="left">Post exposure prophylaxis</td>
    <td align="left">HCQ PBO</td>
    <td align="left">1500</td>
    <td align="left">United States</td>
    <td align="left">NCT04308668</td>
   </tr>
  </tbody>
 </table>
 <table-wrap-foot>
  <fn>
   <p>HCQ-hydroxychloroquine, PBO- placebo, N - number.</p>
  </fn>
 </table-wrap-foot>
</table-wrap>
